RNS Number : 7789Z
Renalytix PLC
27 January 2022
Renalytix plc
("Renalytix" or the "Company")
Renalytix to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
New York and SALT LAKE CITY, January 27, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will be presenting at the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.
Renalytix's management is scheduled to participate in a fireside chat on Tuesday, February 15, 2022, at 3:30 p.m. EST. Due to the format of this virtual event the presentation will not be webcast. The company will be available for virtual 1X1 meetings with investors registered for the event.
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage CKD progression risk assessment. The Company's lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
For further information, please contact:
|
Renalytix plc
|
www.renalytix.com
|
|
James McCullough, CEO
|
Via Walbrook PR
|
|
|
|
|
Stifel (Nominated Adviser, Joint Broker)
|
Tel: 020 7710 7600
|
|
Alex Price / Nicholas Moore
|
|
|
|
|
|
Investec Bank plc (Joint Broker)
|
Tel: 020 7597 4000
|
|
Gary Clarence / Daniel Adams
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com
|
|
Paul McManus / Lianne Applegarth
|
Mob: 07980 541 893 / 07584 391 303
|
|
|
|
|
CapComm Partners
|
|
|
Peter DeNardo
|
Tel: 415-389-6400 or investors@renalytix.com
|
| |
|
|
|
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the
London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS
UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from
UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
NRAFIFIILFIDFIF
